{"id":"NCT00699608","sponsor":"GlaxoSmithKline","briefTitle":"An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.","officialTitle":"A Randomised, Double-blind, Double-dummy, Placebo-controlled, 3-way Crossover Study to Evaluate Potential Next-day Residual Effects of a Single Evening Dose of 3mg Eszopiclone and 7.5mg Zopiclone in Healthy Adult Subjects.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2008-06-18","resultsPosted":"2010-05-12","lastUpdate":"2012-06-05"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Healthy Subjects","Sleep Initiation and Maintenance Disorders"],"interventions":[{"type":"DRUG","name":"GSK1755165; placebo; zopiclone","otherNames":[]}],"arms":[{"label":"Crossover","type":"EXPERIMENTAL"}],"summary":"This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.","primaryOutcome":{"measure":"Mean Tracking Error Assessed During the Continuous Tracking Test (CTT)","timeFrame":"7.5, 8, 8.5, 9, and 9.5 hours post-dose (double-blind)","effectByArm":[{"arm":"Placebo","deltaMin":10.29,"sd":0.625},{"arm":"Eszopiclone","deltaMin":12.49,"sd":0.634},{"arm":"Zopiclone","deltaMin":13.48,"sd":0.621}],"pValues":[{"comp":"OG001 vs OG002","p":"0.267"}]},"eligibility":{"minAge":"25 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":89},"commonTop":["Dysgeusia","Somnolence","Fatigue","Nausea","Dizziness"]}}